PXDN and adenocarcinoma: We found that higher expression of PXDN was significantly associated with shorter survival of adenocarcinoma patients (hazard ratio (HR) = 1.57; 95% confidence interval (CI), 1.05–2.37; P = 0.028, log-rank test), whereas that of ADAMTS16 was not (Figure 4F).